A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary CLL cells and transformed B-cell lymphoma cell line via a caspase- and Bcl-2-independent mechanism.
Johnson
Amy J
AJ
Division of Hematology and Oncology, Department of Internal Medicine, The Ohio State University, 320 W 10th Ave, Columbus, OH 43210, USA.
Smith
Lisa L
LL
Zhu
Jiuxiang
J
Heerema
Nyla A
NA
Jefferson
Sara
S
Mone
Andrew
A
Grever
Michael
M
Chen
Ching-Shih
CS
Byrd
John C
JC
D017209:Apoptosis / Q000187:drug effects*; D020169:Caspases / Q000378:metabolism; D002471:Cell Transformation, Neoplastic / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy / Q000378:metabolism*; D016393:Lymphoma, B-Cell / Q000188:drug therapy / Q000378:metabolism*; D008928:Mitochondria / Q000378:metabolism; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D011720:Pyrazoles / Q000494:pharmacology* / Q000627:therapeutic use; D013449:Sulfonamides / Q000494:pharmacology* / Q000627:therapeutic use; D014407:Tumor Cells, Cultured
C500894:OSU 03012; D019253:Proto-Oncogene Proteins c-bcl-2; D011720:Pyrazoles; D013449:Sulfonamides; D020169:Caspases